1. Home
  2. LUNG vs VNDA Comparison

LUNG vs VNDA Comparison

Compare LUNG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$1.77

Market Cap

72.2M

Sector

Health Care

ML Signal

N/A

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

N/A

Current Price

$9.33

Market Cap

474.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LUNG
VNDA
Founded
1995
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.2M
474.0M
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
LUNG
VNDA
Price
$1.77
$9.33
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$5.38
$14.90
AVG Volume (30 Days)
646.6K
3.7M
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
7.64
N/A
EPS
N/A
N/A
Revenue
$90,497,000.00
$216,105,000.00
Revenue This Year
$6.20
$21.50
Revenue Next Year
$21.61
$38.67
P/E Ratio
N/A
N/A
Revenue Growth
8.01
8.72
52 Week Low
$1.31
$3.81
52 Week High
$8.10
$9.91

Technical Indicators

Market Signals
Indicator
LUNG
VNDA
Relative Strength Index (RSI) 54.59 62.52
Support Level $1.44 $7.39
Resistance Level $1.97 $9.60
Average True Range (ATR) 0.17 0.61
MACD 0.04 0.18
Stochastic Oscillator 47.33 72.49

Price Performance

Historical Comparison
LUNG
VNDA

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: